ArticleDiscover oncology2024

Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer.

Xuhua Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.